Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer
C&EN reports on a significant development in the pharmaceutical industry: the cancellation of a deal between Solstice and Element, along with the FDA’s approval of daraxonrasib for the treatment of pancreatic cancer.